Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingmar Wolff

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Aktuelle Urologie|June 13, 2018
[Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study]Ingmar Wolff, Matthias May, Bernd Hoschke, et al.
Cancer Letters|February 14, 2006
Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladderFrank Christoph, Steffen Weikert, Ingmar Wolff, et al.
Plos One|October 12, 2012
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patientsHellmuth A Meyer, Tobias Endermann, Carsten Stephan, et al.
Urologia Internationalis|November 13, 2019
Gender-Specific Variations in Professional and Personal Aspects among Senior Urology Physicians at German Centers: Results of a Web-Based SurveyUlrike Necknig, Ingmar Wolff, Johannes Bründl, et al.
Aktuelle Urologie|July 8, 2026
[From Opportunistic PSA Testing to Individualized, Risk-Adapted Early Detection of Prostate Cancer in Germany]Matthias May, Maximilian Burger, Ingmar Wolff, et al.
Healthcare (Basel, Switzerland)|March 28, 2026
Changes in PSA-Based Early Detection of Prostate Cancer over a 12-Year Period: Findings from the German KABOT StudyKay-Patrick Braun, Torsten Vogel, Matthias May, et al.
Plos One|October 3, 2013
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinomaJuana Dornbusch, Aristeidis Zacharis, Matthias Meinhardt, et al.
Scientific Reports|April 23, 2024
Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiologyMaryna Somova, Stefan Simm, Adventina Padmyastuti, et al.
European Urology|August 2, 2011
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitorsJonas Busch, Christoph Seidel, Carsten Kempkensteffen, et al.
BMC Cancer|July 16, 2011
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaJonas Busch, Christoph Seidel, Steffen Weikert, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Aktuelle Urologie|June 13, 2018
[Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study]Ingmar Wolff, Matthias May, Bernd Hoschke, et al.
Cancer Letters|February 14, 2006
Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladderFrank Christoph, Steffen Weikert, Ingmar Wolff, et al.
Plos One|October 12, 2012
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patientsHellmuth A Meyer, Tobias Endermann, Carsten Stephan, et al.
Urologia Internationalis|November 13, 2019
Gender-Specific Variations in Professional and Personal Aspects among Senior Urology Physicians at German Centers: Results of a Web-Based SurveyUlrike Necknig, Ingmar Wolff, Johannes Bründl, et al.
Aktuelle Urologie|July 8, 2026
[From Opportunistic PSA Testing to Individualized, Risk-Adapted Early Detection of Prostate Cancer in Germany]Matthias May, Maximilian Burger, Ingmar Wolff, et al.
Healthcare (Basel, Switzerland)|March 28, 2026
Changes in PSA-Based Early Detection of Prostate Cancer over a 12-Year Period: Findings from the German KABOT StudyKay-Patrick Braun, Torsten Vogel, Matthias May, et al.
Plos One|October 3, 2013
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinomaJuana Dornbusch, Aristeidis Zacharis, Matthias Meinhardt, et al.
Scientific Reports|April 23, 2024
Integrating tumor and healthy epithelium in a micro-physiology multi-compartment approach to study renal cell carcinoma pathophysiologyMaryna Somova, Stefan Simm, Adventina Padmyastuti, et al.
European Urology|August 2, 2011
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitorsJonas Busch, Christoph Seidel, Carsten Kempkensteffen, et al.
BMC Cancer|July 16, 2011
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaJonas Busch, Christoph Seidel, Steffen Weikert, et al.
Pageof 5